6 days ago
Definium Therapeutics, Inc. (NASDAQ:DFTX) has now delivered a third consecutive positive Phase 3 readout for its LSD-based medication, the second in generalized anxiety disorder. The result puts the company on a viable route toward a potential FDA approval of an LSD-based treatment for generalized anxiety disorder, and considering how closely psychedelic stocks have historically traded on each other's data, the reading carries far more weight than Definium's own ticker.
On September 14, Definium Therapeutics, Inc. (NASDAQ:DFTX) announced that its drug DT120, an orally disintegrating tablet formulation of LSD, was successful in Panorama, the company's second late-stage anxiety trial. Over 12 weeks, patients who received a 100-microgram dose experienced a 9.8-point decline on the Hamilton Anxiety Rating Scale, a typical clinical measure, compared to a 4.7-point drop with placebo.
The resulting 5.1-point placebo-adjusted improvement is similar to what the company's first pivotal anxiety trial, Voyage, showed back in August: an 11.6-point improvement versus 6.2 for placebo, a 5.4-point separation that Jefferies called one of the strongest placebo-adjusted efficacy results ever seen in generalized anxiety disorder, and that Stifel simply described as "a clean win."
Psychedelic equities have a history of trading as a group rather than as individual names, and this tendency applies both ways. In February 2026, when Compass Pathways, the sector's other clinical leader developing a psilocybin-based drug for treatment-resistant depression, reported positive late-stage data, shares of Definium Therapeutics, Inc. (NASDAQ:DFTX), Atai Beckley, GH Research, and Helus Pharma all rose, some by double digits.
That correlation is significant here because Definium's win is an independent validation of the broader therapeutic argument on which Compass and others are betting: a single dose of a classic psychedelic, administered in a controlled clinical setting, can produce lasting improvements in serious mental health conditions via pathways different from existing SSRIs and other standard-of-care drugs.
#definium #placebo
On September 14, Definium Therapeutics, Inc. (NASDAQ:DFTX) announced that its drug DT120, an orally disintegrating tablet formulation of LSD, was successful in Panorama, the company's second late-stage anxiety trial. Over 12 weeks, patients who received a 100-microgram dose experienced a 9.8-point decline on the Hamilton Anxiety Rating Scale, a typical clinical measure, compared to a 4.7-point drop with placebo.
The resulting 5.1-point placebo-adjusted improvement is similar to what the company's first pivotal anxiety trial, Voyage, showed back in August: an 11.6-point improvement versus 6.2 for placebo, a 5.4-point separation that Jefferies called one of the strongest placebo-adjusted efficacy results ever seen in generalized anxiety disorder, and that Stifel simply described as "a clean win."
Psychedelic equities have a history of trading as a group rather than as individual names, and this tendency applies both ways. In February 2026, when Compass Pathways, the sector's other clinical leader developing a psilocybin-based drug for treatment-resistant depression, reported positive late-stage data, shares of Definium Therapeutics, Inc. (NASDAQ:DFTX), Atai Beckley, GH Research, and Helus Pharma all rose, some by double digits.
That correlation is significant here because Definium's win is an independent validation of the broader therapeutic argument on which Compass and others are betting: a single dose of a classic psychedelic, administered in a controlled clinical setting, can produce lasting improvements in serious mental health conditions via pathways different from existing SSRIs and other standard-of-care drugs.
#definium #placebo
12 days ago
BECKLEY, WV (WVNS) - Volunteers have started planning for the return of the Beckley 5k and Half Marathon event.
Community groups get involved at Beckley's Kids Classic Festival
Members of Active Southern West Virginia have partnered with the Beckley-Raleigh County Chamber of Commerce to present the race.
Participants will start and finish at the Beckley Exhibition Coal Mine. Top place finishers could even walk away with a medal for their efforts! Organizers said all proceeds raised will go to a good cause.
"All the funds raised from this and other Active Southern West Virginia events help us to offer free community activities - things like workplace wellness, our kids' run club in schools," said Jenni Canterbury, Development Director with Active Southern West Virginia."
The half marathon is scheduled to kick off at 8:00 the morning of Saturday, September 26th, while the 5k will get started at 8:30 the same morning.
Those interested can go online for more details including information on how to register and how to get involved with volunteering on event day.
#beckley #southern
Community groups get involved at Beckley's Kids Classic Festival
Members of Active Southern West Virginia have partnered with the Beckley-Raleigh County Chamber of Commerce to present the race.
Participants will start and finish at the Beckley Exhibition Coal Mine. Top place finishers could even walk away with a medal for their efforts! Organizers said all proceeds raised will go to a good cause.
"All the funds raised from this and other Active Southern West Virginia events help us to offer free community activities - things like workplace wellness, our kids' run club in schools," said Jenni Canterbury, Development Director with Active Southern West Virginia."
The half marathon is scheduled to kick off at 8:00 the morning of Saturday, September 26th, while the 5k will get started at 8:30 the same morning.
Those interested can go online for more details including information on how to register and how to get involved with volunteering on event day.
#beckley #southern
1 month ago
Image source: The Motley Fool.
Friday, Aug. 14, 2026 at 5:00 p.m. ET
Chief Executive Officer - Stephen Hood
Chief Financial Officer - Peter Hansen-Chambers
Chief Accounting and Compliance Officer - Stanley Beckley
#motley #executive #hood #financial
Friday, Aug. 14, 2026 at 5:00 p.m. ET
Chief Executive Officer - Stephen Hood
Chief Financial Officer - Peter Hansen-Chambers
Chief Accounting and Compliance Officer - Stanley Beckley
#motley #executive #hood #financial
1 month ago
There was a bit of uncertainty going into last season for Woodrow Wilson's perennially contending volleyball team. The Flying Eagles were going to have to traverse the season with the loss of five seniors who not only started, but were among the best to ever play the sport at the Beckley school.
It took some work, but the new stars all meshed and took the Flying Eagles to their sixth consecutive state tournament appearance.
Now, the team is in somewhat of a similar situation in having to replace four talented seniors in all-staters Anya Hasan (hitter/blocker) and Londen Baker (libero/defensive specialist), DS Zoie Vance and setter Makayla Adkins.
"They were all in key spots," coach Bre Rhodes said. "All four of them had a role on the team. To lose players like that, you take a big hit."
Rhodes is carrying nine players on the varsity roster to start the season, but she had plenty of depth — much of it unexpected — from which to choose.
#Eagles
It took some work, but the new stars all meshed and took the Flying Eagles to their sixth consecutive state tournament appearance.
Now, the team is in somewhat of a similar situation in having to replace four talented seniors in all-staters Anya Hasan (hitter/blocker) and Londen Baker (libero/defensive specialist), DS Zoie Vance and setter Makayla Adkins.
"They were all in key spots," coach Bre Rhodes said. "All four of them had a role on the team. To lose players like that, you take a big hit."
Rhodes is carrying nine players on the varsity roster to start the season, but she had plenty of depth — much of it unexpected — from which to choose.
#Eagles
1 month ago
There were plenty of positive layers to Greater Beckley Christian's golf season in 2025.
It was about perseverance. It was about history. It was about building. It was about winning.
The Crusaders won their first regional championship and played in the state tournament for the first time since 2002, creating memories they'll always carry.
"It had been 23 years since Greater Beckley had done that, so that was awesome for the kids and the community," said head coach Mickey Carr. "It made them feel good about what they'd accomplished."
They did it all with a young team, only two seniors in Eli Gunter and Paul Fox. Gunter was the only senior among the four who played in the state tournament. Yet the young group put it all together.
#played #since
It was about perseverance. It was about history. It was about building. It was about winning.
The Crusaders won their first regional championship and played in the state tournament for the first time since 2002, creating memories they'll always carry.
"It had been 23 years since Greater Beckley had done that, so that was awesome for the kids and the community," said head coach Mickey Carr. "It made them feel good about what they'd accomplished."
They did it all with a young team, only two seniors in Eli Gunter and Paul Fox. Gunter was the only senior among the four who played in the state tournament. Yet the young group put it all together.
#played #since
2 months ago
Eli Lilly (NYSE:LLY) delivered a quarter that forced Wall Street to catch up to its own numbers. On August 5, the company reported second-quarter revenue of $23.0 billion, up 48% from a year earlier, and used the momentum to raise its full-year sales and profit targets. Shares moved higher the same day as investors focused on how fast the obesity franchise is still expanding.
The headline number came from Mounjaro and Zepbound. Mounjaro revenue jumped 91% to $9.9 billion, while Zepbound climbed 46% to $4.9 billion, and together they anchored a quarter where US sales rose 33% to $14.4 billion, and international sales rose 80% to $8.6 billion. Growth was not confined to the diabetes and obesity lineup either. Lilly's immunology, oncology, and neuroscience products grew a combined 121%, showing the newer parts of the portfolio are starting to contribute in a real way.
Management responded by lifting full-year revenue guidance to a range of $85 billion to $87 billion, up from $82 billion to $85 billion previously. Lilly is also plowing the cash back into its pipeline, closing acquisitions of Orna Therapeutics, Ajax Therapeutics, Centessa Pharmaceuticals, and Kelonia Therapeutics during the quarter, agreeing to buy AtaiBeckley afterward, and committing another $4.5 billion to expand manufacturing in Indiana. On the drug development side, three more Phase 3 trials of the experimental triple agonist retatrutide read out positively, giving Lilly a complete data package to support a planned obesity application submission in the first quarter of 2027.
The same quarter that produced 48% revenue growth also showed what that growth is costing. Realized prices fell 13% company-wide, with international pricing down 36% largely tied to Mounjaro's addition to China's national reimbursement drug list, a trade-off Lilly is making for volume and market access. The acquisition spree carried a real accounting price tag too. Acquired R&D charges hit $2.8 billion in the quarter, versus just $154 million a year earlier, which is why reported EPS grew only 26% even as the non-GAAP figure grew 33%.
Asset impairment and restructuring charges of $703 million, largely tied to the Kelonia and Centessa deals, added further drag, and the effective tax rate climbed to 23.3% from 16.5% because of the non-deductible nature of those charges. R&D spending rose 14% to $3.8 billion, and marketing and administrative costs rose 25% to $3.4 billion, a reminder that funding a pipeline this active and prepping for a wave of new launches is not cheap. None of this changes the underlying growth story, but it does mean the path from strong sales to clean reported profit is getting ****** pier as the deal-making continues.
#billion #lilly #therapeutics #reported
The headline number came from Mounjaro and Zepbound. Mounjaro revenue jumped 91% to $9.9 billion, while Zepbound climbed 46% to $4.9 billion, and together they anchored a quarter where US sales rose 33% to $14.4 billion, and international sales rose 80% to $8.6 billion. Growth was not confined to the diabetes and obesity lineup either. Lilly's immunology, oncology, and neuroscience products grew a combined 121%, showing the newer parts of the portfolio are starting to contribute in a real way.
Management responded by lifting full-year revenue guidance to a range of $85 billion to $87 billion, up from $82 billion to $85 billion previously. Lilly is also plowing the cash back into its pipeline, closing acquisitions of Orna Therapeutics, Ajax Therapeutics, Centessa Pharmaceuticals, and Kelonia Therapeutics during the quarter, agreeing to buy AtaiBeckley afterward, and committing another $4.5 billion to expand manufacturing in Indiana. On the drug development side, three more Phase 3 trials of the experimental triple agonist retatrutide read out positively, giving Lilly a complete data package to support a planned obesity application submission in the first quarter of 2027.
The same quarter that produced 48% revenue growth also showed what that growth is costing. Realized prices fell 13% company-wide, with international pricing down 36% largely tied to Mounjaro's addition to China's national reimbursement drug list, a trade-off Lilly is making for volume and market access. The acquisition spree carried a real accounting price tag too. Acquired R&D charges hit $2.8 billion in the quarter, versus just $154 million a year earlier, which is why reported EPS grew only 26% even as the non-GAAP figure grew 33%.
Asset impairment and restructuring charges of $703 million, largely tied to the Kelonia and Centessa deals, added further drag, and the effective tax rate climbed to 23.3% from 16.5% because of the non-deductible nature of those charges. R&D spending rose 14% to $3.8 billion, and marketing and administrative costs rose 25% to $3.4 billion, a reminder that funding a pipeline this active and prepping for a wave of new launches is not cheap. None of this changes the underlying growth story, but it does mean the path from strong sales to clean reported profit is getting ****** pier as the deal-making continues.
#billion #lilly #therapeutics #reported
2 months ago
Dereck Lively II covered the cost of admission for all 105 campers at a free four-hour hoop camp he hosted Saturday at Beckley-Saner Recreation Center in Oak Cliff. The Dallas Mavericks center ran the event in conjunction with Mavs Academy. Lively served as the featured coach. He led drills, refereed scrimmages, contested shots in the paint, and put campers through a series of push-up challenges. Lunch was provided for every participant. Campers also received swag bags that contained T-shirts and autographed photos.
This article originally appeared on Hoops Hype: Dereck Lively II covered the cost of admission for all …
#lively #cost #admission #beckley
This article originally appeared on Hoops Hype: Dereck Lively II covered the cost of admission for all …
#lively #cost #admission #beckley
2 months ago
BECKLEY, W.Va. — Potomac Valley Post 64 kicks off its West Virginia American Legion state tournament run on Thursday.
Post 64 (11-9-1) opens against 19-time state champion and two-time defending **** le-winner Wheeling Post 1 (24-7) at 1 p.m.
All games during the double-elimination tournament will be played at Linda K. Epling Stadium in Beckley, West Virginia.
Potomac Valley advanced to states by virtue of finishing second in the Area 4 tournament, falling to Berkeley Post 14, 2-1, in a best-of-three series last week in Martinsburg.
Berkeley (17-7) plays in the tourney's first game against Parkersburg Post 15 (17-9) at 10 a.m.
#post #tournament #valley #state
Post 64 (11-9-1) opens against 19-time state champion and two-time defending **** le-winner Wheeling Post 1 (24-7) at 1 p.m.
All games during the double-elimination tournament will be played at Linda K. Epling Stadium in Beckley, West Virginia.
Potomac Valley advanced to states by virtue of finishing second in the Area 4 tournament, falling to Berkeley Post 14, 2-1, in a best-of-three series last week in Martinsburg.
Berkeley (17-7) plays in the tourney's first game against Parkersburg Post 15 (17-9) at 10 a.m.
#post #tournament #valley #state
2 months ago
Concerned about an AI bubble? Sign up for The Daily Upside for smart and actionable market news, built for investors.
Wall Street has a new message for TSMC, straight out of The Godfather: Take the profits, leave the capex.
Despite announcing record revenue of $40 billion (beating expectations), net income of $22 billion (a 77% year-over-year increase) and beefed-up guidance for the rest of the year, US-listed shares of the premier semiconductor manufacturer still dropped more than 2% on Thursday following its second-quarter earnings call. Why? Because TSMC also pledged to invest an additional $100 billion (yes, billion) into its Arizona-based chip fab, igniting enough concern about AI over-investment on Wall Street to burn the rest of the sector with it.
Sign up for The Daily Upside at no cost for premium ******* ysis on all your favorite stocks.
READ ALSO: Lackluster Retail Sales Mask a (Short-Lived) Silver Lining and Eli Lilly to Pay up to $3.8B for AtaiBeckley in Big Pharma's Latest Psychedelic Foray
Wall Street has a new message for TSMC, straight out of The Godfather: Take the profits, leave the capex.
Despite announcing record revenue of $40 billion (beating expectations), net income of $22 billion (a 77% year-over-year increase) and beefed-up guidance for the rest of the year, US-listed shares of the premier semiconductor manufacturer still dropped more than 2% on Thursday following its second-quarter earnings call. Why? Because TSMC also pledged to invest an additional $100 billion (yes, billion) into its Arizona-based chip fab, igniting enough concern about AI over-investment on Wall Street to burn the rest of the sector with it.
Sign up for The Daily Upside at no cost for premium ******* ysis on all your favorite stocks.
READ ALSO: Lackluster Retail Sales Mask a (Short-Lived) Silver Lining and Eli Lilly to Pay up to $3.8B for AtaiBeckley in Big Pharma's Latest Psychedelic Foray
2 months ago
Concerned about an AI bubble? Sign up for The Daily Upside for smart and actionable market news, built for investors.
Headline numbers don't tell the whole story.
Retail sales rose 0.2% in June from the prior month, the Commerce Department reported Thursday, a sharp decline from May's revised 1% increase and lagging the 0.3% that economists polled by FactSet expected. There's a reason that's a good thing.
Sign up for The Daily Upside at no cost for premium **** ysis on all your favorite stocks.
READ ALSO: Wall Street Balks at TSMC's $100 Billion Bet on Growing AI Demand and Eli Lilly to Pay up to $3.8B for AtaiBeckley in Big Pharma's Latest Psychedelic Foray
Headline numbers don't tell the whole story.
Retail sales rose 0.2% in June from the prior month, the Commerce Department reported Thursday, a sharp decline from May's revised 1% increase and lagging the 0.3% that economists polled by FactSet expected. There's a reason that's a good thing.
Sign up for The Daily Upside at no cost for premium **** ysis on all your favorite stocks.
READ ALSO: Wall Street Balks at TSMC's $100 Billion Bet on Growing AI Demand and Eli Lilly to Pay up to $3.8B for AtaiBeckley in Big Pharma's Latest Psychedelic Foray
2 months ago
AtaiBeckley (NASDAQ:ATAI), a clinical-stage mental health and psychedelic drug developer, closed at $7.15, up 33.4%. Eli Lilly's (NYSE:LLY) announced acquisition drove the move, and investors are watching the deal terms and closing process. Trading volume reached 164.9M shares, coming in about 1,494% above its three-month average of 10.3M shares. AtaiBeckley IPO'd in 2021 and has fallen 64% since going public.
The S&P 500 (SNPINDEX:^GSPC) fell 0.50% to 7,535, and the Nasdaq Composite (NASDAQINDEX:^IXIC) fell 1.47% to 25,882. Among clinical-stage biopharmaceuticals focused on mental health and psychedelic therapeutics, COMPASS Pathways (NASDAQ:CMPS) fell 6.61% to $12.43, while broader psychedelics sentiment stayed tied to AtaiBeckley's Lilly deal.
Pharmaceutical behemoth Eli Lilly acquired AtaiBeckley in a purchase worth up to $3.8 billion today, sending the latter's shares 34% higher. The deal consists of $6.75 in cash per ATAI share, as well as $2.50 in contingent value rights (CVRs) tied to two of AtaiBeckley's treatments meeting certain milestones over the next four, five, and seven years.
Thanks to the value of these CVRs, ATAI's $7.15 share price currently sits above the $6.75 cash portion of the deal, suggesting the market sees potential in AtaiBeckley's psychedelic treatments reaching their various milestones. AtaiBeckley offers DMT and other psychedelic treatments for depression, anxiety, and opioid use disorder, and has seen its stock double over the last year thanks to today's deal and the Trump administration's positive outlook on psychedelic-based treatments.
Before you buy stock in AtaiBeckley, consider this:
The S&P 500 (SNPINDEX:^GSPC) fell 0.50% to 7,535, and the Nasdaq Composite (NASDAQINDEX:^IXIC) fell 1.47% to 25,882. Among clinical-stage biopharmaceuticals focused on mental health and psychedelic therapeutics, COMPASS Pathways (NASDAQ:CMPS) fell 6.61% to $12.43, while broader psychedelics sentiment stayed tied to AtaiBeckley's Lilly deal.
Pharmaceutical behemoth Eli Lilly acquired AtaiBeckley in a purchase worth up to $3.8 billion today, sending the latter's shares 34% higher. The deal consists of $6.75 in cash per ATAI share, as well as $2.50 in contingent value rights (CVRs) tied to two of AtaiBeckley's treatments meeting certain milestones over the next four, five, and seven years.
Thanks to the value of these CVRs, ATAI's $7.15 share price currently sits above the $6.75 cash portion of the deal, suggesting the market sees potential in AtaiBeckley's psychedelic treatments reaching their various milestones. AtaiBeckley offers DMT and other psychedelic treatments for depression, anxiety, and opioid use disorder, and has seen its stock double over the last year thanks to today's deal and the Trump administration's positive outlook on psychedelic-based treatments.
Before you buy stock in AtaiBeckley, consider this:
2 months ago
AtaiBeckley N.V. (NASDAQ:ATAI) is one of the 10 best stocks under $10 that could triple.
On June 25, AtaiBeckley N.V. (NASDAQ:ATAI) shared that the company will be included in the Russell indices following their latest reconstitution. The stock will become a part of the small-cap focused Russell 2000 Index, as well as the broader Russell 3000 Index, effective from June 29 onwards.
Likoper/Shutterstock.com
The company highlighted this as a significant development since more than $12 trillion worth of ****** ets are benchmarked relative to the Russell indexes. The Russell 2000 Index tracks around 2,000 small-cap stocks, while the Russell 3000 Index covers around 3,000 small-, mid-, and large-cap stocks.
Later on July 7, Canaccord Genuity increased the price target on AtaiBeckley N.V. (NASDAQ:ATAI) from $15 to $17, resulting in an adjusted upside potential of over 227%. The firm also reiterated its Buy rating on the stock.
On June 25, AtaiBeckley N.V. (NASDAQ:ATAI) shared that the company will be included in the Russell indices following their latest reconstitution. The stock will become a part of the small-cap focused Russell 2000 Index, as well as the broader Russell 3000 Index, effective from June 29 onwards.
Likoper/Shutterstock.com
The company highlighted this as a significant development since more than $12 trillion worth of ****** ets are benchmarked relative to the Russell indexes. The Russell 2000 Index tracks around 2,000 small-cap stocks, while the Russell 3000 Index covers around 3,000 small-, mid-, and large-cap stocks.
Later on July 7, Canaccord Genuity increased the price target on AtaiBeckley N.V. (NASDAQ:ATAI) from $15 to $17, resulting in an adjusted upside potential of over 227%. The firm also reiterated its Buy rating on the stock.
4 months ago
Beckley ribbon-cutting ceremony held for NRGRDA textile program and workshop
BECKLEY — The New River Gorge region’s outdoor economy gained a new thread May 21 in downtown Beckley.
The PATTERN Textile Training and Manufacturing Center opened with a ribbon cutting and open house at the United Bank Building on Main Street. The center is an initiative of the New River Gorge Regional Development Authority aimed at expanding cut-and-sew training, textile product development and business support in Southern West Virginia.
Amy Showalter, a community ******* et lead for the NRGRDA, spoke at the ceremony and said the project has been developing in the region for years before reaching Thursday’s opening.
“PATTERN, or Planning and Accelerating Textile Technology and Entrepreneurship Regional Network, is an initiative of the New River Gorge Regional Development Authority,” Showalter said. “But it is also something that has been building in the region for years, and we are excited to take this next pivotal step in the journey.”
Emily Rouse, a textile industry consultant for PATTERN, said the effort took several years and involved a team working across state lines to source machines, prepare the facility and ******* s local industry needs.
https://www.yahoo.com/news...
BECKLEY — The New River Gorge region’s outdoor economy gained a new thread May 21 in downtown Beckley.
The PATTERN Textile Training and Manufacturing Center opened with a ribbon cutting and open house at the United Bank Building on Main Street. The center is an initiative of the New River Gorge Regional Development Authority aimed at expanding cut-and-sew training, textile product development and business support in Southern West Virginia.
Amy Showalter, a community ******* et lead for the NRGRDA, spoke at the ceremony and said the project has been developing in the region for years before reaching Thursday’s opening.
“PATTERN, or Planning and Accelerating Textile Technology and Entrepreneurship Regional Network, is an initiative of the New River Gorge Regional Development Authority,” Showalter said. “But it is also something that has been building in the region for years, and we are excited to take this next pivotal step in the journey.”
Emily Rouse, a textile industry consultant for PATTERN, said the effort took several years and involved a team working across state lines to source machines, prepare the facility and ******* s local industry needs.
https://www.yahoo.com/news...
